QVA149, trial medicine by Novartis for the treatment of chronic obstructive pulmonary disease (COPD), has achieved the required therapeutic targets in three late-stage clinical trials.
[hana-code-insert name=’StumbleUpon’ /][hana-code-insert name=’Reddit’ /] Novartis, the Swiss pharmaceutical company, has reported on Monday, April 02, 2012 that three of the ten trials in IGNITE program i.e. SHINE, BRIGHT and ENLIGHTEN studies have met their required goal for QVA149 studies while the remaining seven would be completed by this year.
COPD is the lung disease and is among the common diseases. It is a progressive disease and causes difficulty in breathing. One of the first signs of this disease is coughing up mucus. It is suggested to be the third biggest cause of death in the world by 2020 as reported by Novartis. Many of the pharmaceutical companies are working hard to get potential business in this regard.
The company’s SHINE trial has shown that QVA149, a combination of Novartis’ Onbrez Breezhaler, or indacaterol, and NVA237, or glycopyrronium bromide, worked better as compared to the individual components’ same doses. The BRIGHT trial with QVA149 showed better results in patients who did exercise i.e. the patients showed more endurance to exercise. The ENLIGHTEN studies showed well-tolerance.
“Meeting the primary endpoints in the IGNITE Phase III clinical trial program signals significant progress in establishing the potential of QVA149, which is expected to be the third innovative medicine in our strong COPD portfolio,” said Tim Wright, Head of Development, Novartis Pharmaceuticals. “Novartis is committed to addressing the unmet needs of COPD patients and improving their quality of life by providing innovative medicines and devices.”
Despite of the potential success of QVA149, the company has to compete with GlaxoSmithKline’s (GSK’s) Seretide or Advair, which is a best-seller for the company.